Sponsored by
Very interesting research. They took many biopsies from each tumor and mapped them. They found that there is a lot of variation between areas of the tumor, to the point where it almost doesn't make sense to use a targeted treatment based on just a single biopsy. Even MGMT methylations levels varied a lot from different areas of the tumor. This reinforces the concept used by DCVAX - which uses tumor lysate to try to make the vaccine against all of the targets found throughout the tumor instead of trying to pick the one or handful of most important targets from a single biopsy.